ONCY

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design

ONCY: Seeking Registration Pathway for Part B of REO 033 Trial

Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics

Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention

ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study

From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story